Mesalamine

CAS 89-57-6 30 current records 9 historicalSmall Molecule

Who holds supplier records for Mesalamine? 30 organisations hold a current record for Mesalamine: an active US FDA Type II Drug Master File or a CEP. A further 9 organisations have only historical (inactive) DMF filings. 23 of them hold a valid EU Certificate of Suitability (22 holder entries on the EDQM register, listed below). Recorded organisation countries for current records: India (18), China (4), Italy (2), Sweden (1) and 2 other countries (2); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Mesalamine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/mesalamine

Reading the evidence

  • 30 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    18 of the 27 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 16 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Mesalamine expires 1 May 2030. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (30)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Mesalamine. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Mesalamine sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (22)

Certificates of Suitability on the EDQM register for Mesalamine, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 41 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
ZHEJIANG HENGKANG PHARMACEUTICAL CO., LTD. SanmenCN
CEP 2021-400 - Rev 02
Mesalazine, Pubagang site
Sept 2026—
RIZHAO BROTHER PHARMACEUTICAL CO., LTD. RizhaoCN
CEP 2025-097 - Rev 00
Mesalazine
Aug 2026—
ALKEM LABORATORIES LIMITED MumbaiIN
CEP 2025-327 - Rev 00
Mesalazine
Aug 2026—
CHEMI S.P.A. PatricaIT
CEP 2003-188 - Rev 07
Mesalazine, Product codes: FV0950 (milled) and FV0943 (micronised)
Jul 2026Inspected Jul 2025
Italy
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
CEP 2003-267 - Rev 07
Mesalazine
Mar 2026—
D. K. PHARMA CHEM PRIVATE LIMITED BadlapurIN
CEP 2025-039 - Rev 00
Mesalazine
Feb 2026Inspected Mar 2024
Sweden
IPCA LABORATORIES LIMITED MumbaiIN
CEP 2006-122 - Rev 05
Mesalazine
Dec 2025—
BEC CHEMICALS PRIVATE LIMITED MumbaiIN
CEP 2011-100 - Rev 01
Mesalazine
Jun 2025—
MSN LIFE SCIENCES PRIVATE LIMITED Bhiknoor VillageIN
CEP 2024-351 - Rev 00
Mesalazine
Mar 2025—
IOL CHEMICALS AND PHARMACEUTICALS LTD LudhianaIN
CEP 2023-339 - Rev 00
Mesalazine
Jan 2025—
ZYDUS LIFESCIENCES LIMITED VadodaraIN
CEP 2024-395 - Rev 00
Mesalazine, Process-I
Nov 2024—
Syntese A/S HvidovreDK
CEP 2004-056 - Rev 06
Mesalazine
Mar 2024Inspected Feb 2026
Denmark
PHARMAZELL GMBH RaublingDE
CEP 2003-203 - Rev 03
Mesalazine
Nov 2023Inspected Jun 2025
Germany
MAITHRI DRUGS PRIVATE LIMITED Bonthapally VillageIN
R1-CEP 2017-116 - Rev 00
Mesalazine
Apr 2023—
SOLARA ACTIVE PHARMA SCIENCES LIMITED ChennaiIN
R0-CEP 2021-338 - Rev 00
Mesalazine
Jan 2023—
DIVI'S LABORATORIES LIMITED HyderabadIN
R1-CEP 2016-050 - Rev 01
Mesalazine
Nov 2022—
AMOLI ORGANICS PRIVATE LIMITED MumbaiIN
R0-CEP 2020-167 - Rev 00
Mesalazine
Nov 2021—
CAMBREX KARLSKOGA AB KarlskogaSE
R1-CEP 2003-071 - Rev 03
Mesalazine, Grade S
Jun 2021—
CTX LIFESCIENCES PVT. LIMITED SuratIN
R1-CEP 2015-152 - Rev 00
Mesalazine
Jun 2021—
ERREGIERRE S.P.A. San Paolo D'ArgonIT
R1-CEP 2004-049 - Rev 04
Mesalazine
Oct 2019—
JIANGSU JUBANG PHARMACEUTICAL CO., LTD. LiyangCN
R1-CEP 2012-162 - Rev 00
Mesalazine
Mar 2019—
A.H.A International Co., Ltd. HefeiCN
R1-CEP 2010-149 - Rev 00
Mesalazine
Aug 2015—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (9)

Organisations whose Type II DMFs for Mesalamine are no longer active. These show a past filing, not current supply.

Show all 9 historical records
  • India · Inactive DMF 31887 · filed Jul 2017
  • SIGNA SA DE CV
    Inactive DMF 29676 · filed Jan 2016
  • India · Inactive DMF 21514 · filed Mar 2008
  • LUPIN MANUFACTURING SOLUTIONS LTD
    Inactive DMF 21489 · filed Mar 2008
  • India · Inactive DMF 18387 · filed May 2005
  • United States · Inactive DMF 18054 · filed Feb 2005
  • Italy · Inactive DMF 11807 · filed Jan 1996
  • PLIVA CROATIA LTD
    Inactive DMF 10645 · filed Jan 1993
  • CILAG CHEMIE AG
    Inactive DMF 6605 · filed Sept 1986

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (39 listed products contain Mesalamine). The latest listed patent expires 1 May 2030. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Mesalamine is an anti-inflammatory drug used to treat inflammatory bowel diseases, such as ulcerative colitis. It works by inhibiting the production of substances in the lining of the colon that cause inflammation.

Chemical identity

IUPAC name
5-amino-2-hydroxybenzoic acid
Canonical SMILES
C1=CC(=C(C=C1N)C(=O)O)O
InChIKey
KBOPZPXVLCULAV-UHFFFAOYSA-N
Synonyms
apriso, asacol, benzoic acid, 5-amino-2-hydroxy-, canasa, fisalamine, iialda, lialda, max-002, mesalazine, nsc-38877, pentasa, rowasa

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Aminosalicylate
Chemical structure
Aminosalicylic Acids

Therapeutic areas

GastroenterologyInflammatory Bowel Disease

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Mesalamine?

30 organisations hold an active US FDA Type II Drug Master File or a CEP for Mesalamine: ERREGIERRE SPA (Italy), Zydus Lifesciences Limited (India), Alkem Laboratories Limited (India), CHEMI SPA (Italy), Divis Laboratories (India), Iol Chemicals And Pharmaceuticals Limited (India), Ipca Laboratories Limited (India) and MAITHRI DRUGS PRIVATE LTD (India), and 22 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Mesalamine Drug Master Files are active?

ERREGIERRE SPA (DMF 13883, 24889), Zydus Lifesciences Limited (DMF 22999, 27939), Alkem Laboratories Limited (DMF 33939), CHEMI SPA (DMF 11951), Divis Laboratories (DMF 29998), Iol Chemicals And Pharmaceuticals Limited (DMF 38338), Ipca Laboratories Limited (DMF 19261, 27245) and MAITHRI DRUGS PRIVATE LTD (DMF 31570) and 12 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Mesalamine records mean?

9 organisations have only inactive Type II DMFs for Mesalamine. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Mesalamine have a European Certificate of Suitability?

Yes. 23 organisations hold a valid CEP for Mesalamine on the EDQM register, including ZHEJIANG HENGKANG PHARMACEUTICAL CO., LTD. Sanmen (CN), RIZHAO BROTHER PHARMACEUTICAL CO., LTD. Rizhao (CN), ALKEM LABORATORIES LIMITED Mumbai (IN), CHEMI S.P.A. Patrica (IT), SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN) and D. K. PHARMA CHEM PRIVATE LIMITED Badlapur (IN) and 16 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Mesalamine?

Yes. The latest patent listed for an approved US product containing Mesalamine expires 1 May 2030, across 39 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Mesalamine supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Mesalamine?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.